Arkolith/Insider Trading/BCRX/Form 4

Heggie Theresa

DirectorBIOCRYST PHARMACEUTICALS INC (BCRX) · full profile →Form 4 · filed Mar 24, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$505K
Net Open-Market Flow
-$505K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 20, 2026Option exercise(M)50K$6.30$315K115K
Mar 20, 2026Sell(S)50K$10.11$505K65K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 20, 2026Option exercise(M)50K—$00

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000882796-26-000017) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML